(VIANEWS) – Another day of trading has ended and here’s today’s list of stocks that have had significant trading activity in the US session.

The three biggest winners today are FAT Brands, Shopify, and MarketAxess Holdings.

Rank Financial Asset Price Change Updated (EST)
1 FAT Brands (FATBW) 3.48 18.37% 2023-01-25 07:42:16
2 Shopify (SHOP) 47.37 10.96% 2023-01-25 15:50:50
3 MarketAxess Holdings (MKTX) 363.92 10.44% 2023-01-25 15:58:38
4 Capital One Financial (COF) 116.00 8.91% 2023-01-25 15:56:53
5 Editas Medicine (EDIT) 8.83 7.95% 2023-01-25 01:15:12
6 EyePoint Pharmaceuticals (EYPT) 4.55 7.82% 2023-01-25 07:11:10
7 VerifyMe (VRME) 2.02 7.56% 2023-01-25 15:38:38
8 Pacific Biosciences of California (PACB) 11.64 7.33% 2023-01-25 15:59:28
9 ESSA Pharma (EPIX) 2.91 6.59% 2023-01-25 03:12:10
10 AT&T (T) 20.32 6.03% 2023-01-25 15:49:36

The three biggest losers today are Entera Bio Ltd., Whole Earth Brands, and Citius Pharmaceuticals.

Rank Financial Asset Price Change Updated (EST)
1 Entera Bio Ltd. (ENTXW) 0.03 -33.54% 2023-01-25 03:10:10
2 Whole Earth Brands (FREEW) 0.20 -20.8% 2023-01-25 13:11:10
3 Citius Pharmaceuticals (CTXR) 1.19 -15% 2023-01-24 19:12:11
4 DIRTT Environmental Solutions Ltd. (DRTT) 0.78 -10.4% 2023-01-24 23:09:21
5 Frequency Therapeutics (FREQ) 4.98 -9.04% 2023-01-25 13:12:12
6 Erytech Pharma S.A. (ERYP) 0.52 -8.79% 2023-01-25 03:46:17
7 NextEra Energy (NEE) 76.63 -8.66% 2023-01-25 15:55:40
8 Fathom Holdings (FTHM) 5.69 -7.78% 2023-01-25 15:07:35
9 DZS (DZSI) 11.94 -7.44% 2023-01-25 01:10:12
10 Cyclerion Therapeutics (CYCN) 0.63 -7.36% 2023-01-24 19:43:16

Winners today

1. FAT Brands (FATBW) – 18.37%

NASDAQ ended the session with FAT Brands jumping 18.37% to $3.48 on Wednesday while NASDAQ dropped 0.18% to $11,313.36.

Yearly Top and Bottom Value

FAT Brands’s stock is valued at $3.48 at 16:32 EST, below its 52-week high of $3.72 and way above its 52-week low of $2.99.

More news about FAT Brands.

2. Shopify (SHOP) – 10.96%

Shopify Inc. is a commerce company that offers a commerce platform as well as services throughout Canada, America, Europe, Asia Pacific and Latin America. Shopify Inc.’s platform allows merchants to display, manage, market, and sell their products via various channels including online and mobile storesfronts and pop-up shops as well as social media and native apps. It also allows them to process orders and pay, ship and fulfill orders, build relationships with customers, leverage analytics, report, access funding, manage cash and payments, and manage transactions and cash. The company also offers custom themes, apps and domain registration. It can also provide merchant solutions that include processing payments, fulfillment and shipping, as well as securing working capital. The business was previously known as Jaded Pixel Technologies Inc., but it changed its name in November 2011 to Shopify Inc. Shopify Inc. was founded in 2004. It is located in Ottawa, Canada.

NYSE ended the session with Shopify jumping 10.96% to $47.37 on Wednesday while NYSE dropped 0.03% to $15,863.19.

Earnings Per Share

As for profitability, Shopify has a trailing twelve months EPS of $12.79.

PE Ratio

Shopify has a trailing twelve months price to earnings ratio of 3.7. Meaning,
the purchaser of the share is investing $3.7 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -31.98%.

Growth Estimates Quarters

The company’s growth estimates for the current quarter and the next is a negative 107.1% and a negative 150%, respectively.

Earnings before Interest, Taxes and Depreciation

Shopify’s EBITDA stands at -220.6

More news about Shopify.

3. MarketAxess Holdings (MKTX) – 10.44%

MarketAxess Holdings Inc., together with its subsidiaries, operates an electronic trading platform for institutional investor and broker-dealer companies worldwide. It offers the access to liquidity in the U.S. investment-grade bonds, U.S. high-yield bonds, and U.S. Treasuries, as well as municipal bonds, emerging market debts, Eurobonds, and other fixed income securities. The company, through its Open Trading protocols, executes bond trades between and among institutional investor and broker-dealer clients in an all-to-all anonymous trading environment for corporate bonds. It also offers trading-related products and services, including composite+ pricing and other market data products to assist clients with trading decisions; auto-execution and other execution services for clients requiring specialized workflow solutions; connectivity solutions that facilitate straight-through processing; and technology services to optimize trading environments. In addition, the company provides various pre-and post-trade services, such as trade matching, trade publication, regulatory transaction reporting, and market and reference data across a range of fixed-income and other products. MarketAxess Holdings Inc. was incorporated in 2000 and is headquartered in New York, New York.

NASDAQ ended the session with MarketAxess Holdings jumping 10.44% to $363.92 on Wednesday, after two successive sessions in a row of losses. NASDAQ fell 0.18% to $11,313.36, following the last session’s downward trend on what was a somewhat down trend trading session today.

Earnings per Share

MarketAxess Holdings’ trailing 12 months EPS is $8.

PE Ratio

MarketAxess Holdings’ trailing 12-month price-to-earnings ratio is 45.49. The purchaser of the shares is therefore investing $45.49 per dollar in annual earnings.

For the 12 trailing months, the company’s return-on-equity, which is a measure of the profitability and shareholder equity for a business, was 23.45%.

Sales Growth

MarketAxess Holdings saw a 7.3% increase in sales for its current quarter, and an 8.6% rise for the following.

Moving Average

MarketAxess Holdings is worth more than its $50 moving average at $283.55, and much higher than its $200 moving average at $265.17.

Volatility

MarketAxess Holdings had an intraday variation of 0.54% in the last week, last months, and last quarter.

MarketAxess Holdings had the highest average volatility amplitudes at 1.26%, 1.61% and 1.95% respectively (last week, last month, and last quarter).

More news about MarketAxess Holdings.

4. Capital One Financial (COF) – 8.91%

Capital One Financial Corporation is the financial holding company of Capital One Bank (USA), National Association and Capital One National Association. This bank provides a variety of financial products and services throughout the United States and Canada. The company operates in three distinct segments, Credit Card, Consumer Banking and Commercial Banking. Checking accounts, money market deposits and negotiable orders of withdrawals are all accepted. The company offers credit cards, auto and retail bank loans; commercial and multifamily real property loans and industrial loans. It also provides credit and debit cards, online banking services and treasury and depository management services. The company serves small and large businesses as well as consumers through branches, cafes and digital channels. It also has other distribution channels in New York and California. Capital One Financial Corporation was established in 1988. It is located in McLean in Virginia.

NYSE ended the session with Capital One Financial jumping 8.91% to $116.00 on Wednesday, following the last session’s downward trend. NYSE fell 0.03% to $15,863.19, following the last session’s downward trend on what was a somewhat down trend trading session today.

Earnings Per Share

As for profitability, Capital One Financial has a trailing twelve months EPS of $15.3.

PE Ratio

Capital One Financial has a trailing twelve months price to earnings ratio of 7.58. Meaning,
the purchaser of the share is investing $7.58 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 14.95%.

Volume

Today’s last reported volume for Capital One Financial is 9689430 which is 214.66% above its average volume of 3079270.

More news about Capital One Financial.

5. Editas Medicine (EDIT) – 7.95%

Editas Medicine, Inc. is a company that specializes in clinical-stage genome editing. It focuses its efforts on creating transformative genomic medicines for a variety of serious illnesses. The company develops proprietary genetic editing platforms based on CRISPR technology that target specific therapeutic areas and diseases. EDIT-101 is currently in Phase 2 clinical trials for Leber Congenital Amaurosis Type 10, a form of genetic vision loss that can lead to blindness as a child. It is also developing EDIT-102 to treat Usher Syndrome 2A. This form of retinitis can also include hearing loss. The company also develops gene-edited Natural Killer cells medicines for solid tumors, alpha-beta and gamma Delta T cell therapies to combat cancer. It has an early discovery program that will help to create a treatment to treat sickle cell disease or beta-thalassemia. Juno Therapeutics, Inc. is its research partner to create engineered cells to fight cancer. Allergan Pharmaceuticals International Limited has a strategic alliance with them to find, develop, commercialize and market new gene editing drugs for a variety of ocular conditions. Asklepios BioPharmaceutical, Inc. collaborates with AskBio, and m BlueRock Therapeutics LP. Gengine, Inc. was the company’s former name. Editas Medicine, Inc. took over that role in November 2013. Editas Medicine, Inc. is an American corporation that was founded in 2013. Its headquarters are located in Cambridge, Massachusetts.

NASDAQ ended the session with Editas Medicine rising 7.95% to $8.83 on Wednesday while NASDAQ slid 0.18% to $11,313.36.

Earnings per Share

Editas Medicine’s trailing 12 months profit per share is $-2.73.

For the 12 trailing months, the company’s return-on-equity, which is a measure of the profitability and shareholder equity for a business, was negative at -40.16%.

More news about Editas Medicine.

6. EyePoint Pharmaceuticals (EYPT) – 7.82%

EyePoint Pharmaceuticals, Inc., is a pharmaceutical company that develops and markets ophthalmic drugs for treating eye disease in the United States, China, as well as the United Kingdom. ILUVIEN is an intravitreal sustained-release micro-injectable for diabetic macular swelling; YUTIQ is a fluocinolone-acetonide intravitreal insert for intravitreal treatment for chronic non-infectious eye disease. DEXYCU, which contains dexamethasone intraocular suspension for post-operative inflammation. EYP-1901 is a bioerodible, twice-yearly formulation of tyrosinekinase inhibitor. It’s currently in Phase 1 clinical trials. This treatment is for wet age-related retinal degeneration and diabetic retinopathy. YUTIQ50 is for chronic, non-infectious, eye uveitis. Alimera Sciences, Inc., Bausch & Lomb, Ocumension Therapeutics, OncoSil Medical UK Limited, Ocumension Therapeutics, Equinox Science, LLC are some of the strategic partners. ImprimisRx PA, Inc. is also a commercial partner. This alliance promotes DEXYCU, which can be used to treat post-operative inflammation after ocular surgery. The company used to be known as pSivida Corp., but changed its name in March 2018 to EyePoint Pharmaceuticals, Inc. EyePoint Pharmaceuticals, Inc. is located in Watertown, Massachusetts.

NASDAQ ended the session with EyePoint Pharmaceuticals jumping 7.82% to $4.55 on Wednesday while NASDAQ slid 0.18% to $11,313.36.

Earnings Per Share

As for profitability, EyePoint Pharmaceuticals has a trailing twelve months EPS of $-2.105.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -68.3%.

More news about EyePoint Pharmaceuticals.

7. VerifyMe (VRME) – 7.56%

Together with PeriShip Global, LLC, VerifyMe, Inc. operates as a technology solution provider. They specialize in connecting brands and consumers, providing logistics support for brands, and ensuring that their products are delivered on time. Two segments of the company are VerifyMe Solutions or PeriShip Global Solutions. VerifyMe Solutions is a technology segment that connects brands and consumers. This allows brand owners to collect business intelligence, while communicating directly with customers. The solutions it offers provide brand protection, supply chain functions such as authentication, serialization and counterfeit prevention. They also offer track and trace capabilities for packaging labels and products. The segment offers customer engagement, customized printing of tamper-evident labels using visible and invisible variable codes and images printed with proprietary inks. PeriShip Global Solutions offers predictive analytics to optimize delivery time and temperature sensitive perishable goods. PeriTrack’s segment offers customers an integrated portal that gives them a detailed view of their shipping activities using real-time data. The company also offers pre-transit and post-delivery call centers, as well as weather/traffic service. INX International Ink Company is the strategic partner of VerifyMe. The company used to be known as LaserLock Technologies, Inc., but changed its name in July 2015 to VerifyMe, Inc. VerifyMe, Inc. is an American company that was founded in 1999. Its headquarters are in Rochester, New York.

NASDAQ ended the session with VerifyMe jumping 7.56% to $2.02 on Wednesday while NASDAQ dropped 0.18% to $11,313.36.

Earnings Per Share

As for profitability, VerifyMe has a trailing twelve months EPS of $-1.483.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -54.47%.

Sales Growth

VerifyMe sales growth was 2547.1% in the most recent quarter, and 3626.7% the following.

Volume

Today’s last reported volume for VerifyMe is 37360 which is 13.28% above its average volume of 32980.

Growth Estimates Quarters

For the current quarter, the company expects to grow by 57.1% and then 5.3% respectively.

Yearly Top and Bottom Value

VerifyMe’s stock is valued at $2.02 at 16:33 EST, way under its 52-week high of $3.59 and way above its 52-week low of $1.01.

More news about VerifyMe.

8. Pacific Biosciences of California (PACB) – 7.33%

Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing systems to resolve genetically complex problems. The company provides PacBio's Systems, which conduct, monitor, and analyse biochemical sequencing reactions; consumable products, including single molecule real-time (SMRT) cells; and various reagent kits designed for specific workflow, such as template preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. The company serves research institutions; commercial laboratories; genome centers; public health labs, hospitals and clinical research institutes, contract research organizations, and academic institutions; pharmaceutical companies; and agricultural companies. It markets its products through a direct sales force in North America and Europe, as well as through distribution partners in Asia, Europe, the Middle East, Africa, and Latin America. Pacific Biosciences of California, Inc. has a development and commercialization agreement with Invitae Corporation. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.

NASDAQ ended the session with Pacific Biosciences of California jumping 7.33% to $11.64 on Wednesday, following the last session’s downward trend. NASDAQ dropped 0.18% to $11,313.36, following the last session’s downward trend on what was a somewhat negative trend exchanging session today.

Earnings per Share

Pacific Biosciences of California’s trailing 12 months EPS is $-0.34.

For the 12 trailing months, the company’s return-on-equity, which is a measure of the profitability of a company relative to shareholders’ equity, was negative at -43.76%.

Sales Growth

The sales growth at Pacific Biosciences of California is 1.5% in the current quarter, and 4.4% the following.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

Pacific Biosciences of California’s stock is considered to be oversold (<=20).

More news about Pacific Biosciences of California.

9. ESSA Pharma (EPIX) – 6.59%

ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses on developing novel and proprietary therapies for the treatment of prostate cancer. It develops EPI-7386, an oral candidate that is in a Phase I clinical study for the treatment of patients with metastatic castration-resistant prostate cancer. The company has collaboration agreements with Caris Life Sciences, Inc.; Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada.

NASDAQ ended the session with ESSA Pharma jumping 6.59% to $2.91 on Wednesday, after two successive sessions in a row of gains. NASDAQ slid 0.18% to $11,313.36, following the last session’s downward trend on what was a somewhat bearish trend exchanging session today.

Earnings Per Share

As for profitability, ESSA Pharma has a trailing twelve months EPS of $-0.866.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -19.44%.

Volume

ESSA Pharma’s current reported volume is 743182, which is 79.03% lower than its average volume (3555338).

Earnings Before Interest, Taxes, Depreciation, and Amortization

ESSA Pharma’s EBITDA is 14.81.

Yearly Top and Bottom Value

ESSA Pharma’s stock is valued at $2.91 at 16:33 EST, way below its 52-week high of $10.99 and way higher than its 52-week low of $1.40.

Moving Average

ESSA Pharma’s value is under its 50-day moving average of $3.00 and way under its 200-day moving average of $3.56.

More news about ESSA Pharma.

10. AT&T (T) – 6.03%

AT&T Inc. offers telecommunications and media services around the world. The Communications segment provides wireless voice and data communication services. It also sells wireless devices and accessories through third-party retailers, agent stores and company stores. The company also offers managed and professional services and data, voice and security solutions. This segment also offers voice communications services via legacy telephony and broadband fiber to residential customers. The company markets its communication services and products under AT&T’s Cricket, AT&T PREPAID and AT&T Fiber brands. Latin America is the company’s segment that provides services for wireless in Mexico and video in Latin America. The Unefon and AT&T brands are used to market the services and products of this segment. The company used to be known as SBC Communications Inc., but changed its name in 2005 to AT&T Inc. AT&T Inc. was founded in 1983. It is located in Dallas, Texas.

NYSE ended the session with AT&T rising 6.03% to $20.32 on Wednesday, after two consecutive sessions in a row of gains. NYSE slid 0.03% to $15,863.19, following the last session’s downward trend on what was a somewhat negative trend trading session today.

Earnings Per Share

As for profitability, AT&T has a trailing twelve months EPS of $-0.34.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 11.92%.

Revenue Growth

Year-on-year quarterly revenue growth declined by 24.7%, now sitting on 155.32B for the twelve trailing months.

Yearly Top and Bottom Value

AT&T’s stock is valued at $20.32 at 16:33 EST, below its 52-week high of $21.53 and way higher than its 52-week low of $14.46.

Moving Average

AT&T’s worth is above its 50-day moving average of $18.72 and above its 200-day moving average of $18.65.

Dividend Yield

As maintained by Morningstar, Inc., the next dividend payment is on Oct 5, 2022, the estimated forward annual dividend rate is 1.11 and the estimated forward annual dividend yield is 6.16%.

More news about AT&T.

Losers Today

1. Entera Bio Ltd. (ENTXW) – -33.54%

NASDAQ ended the session with Entera Bio Ltd. dropping 33.54% to $0.03 on Wednesday while NASDAQ fell 0.18% to $11,313.36.

Yearly Top and Bottom Value

Entera Bio Ltd.’s stock is valued at $0.03 at 16:33 EST, under its 52-week low of $0.03.

More news about Entera Bio Ltd..

2. Whole Earth Brands (FREEW) – -20.8%

NASDAQ ended the session with Whole Earth Brands falling 20.8% to $0.20 on Wednesday, after five sequential sessions in a row of losses. NASDAQ dropped 0.18% to $11,313.36, following the last session’s downward trend on what was a somewhat negative trend exchanging session today.

Annual Top and Bottom Value

Whole Earth Brands’ stock was valued at $0.20 as of 16:33 EST. This is below its 52 week high of $0.21, and well above its 52 week low of $0.15.

More news about Whole Earth Brands.

3. Citius Pharmaceuticals (CTXR) – -15%

Citius Pharmaceuticals, Inc. is a specialty pharmaceutical firm that develops and markets critical care products. It focuses on the creation and marketing of anti-infective products for adjunct cancer care, prescription drugs, and mesenchymal and stem cell therapy. The company is developing five proprietary products comprising Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome; and I/ONTAK, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma. Citius Pharmaceuticals, Inc., was established in Cranford, New Jersey in 2007.

NASDAQ ended the session with Citius Pharmaceuticals sliding 15% to $1.19 on Wednesday, following the last session’s downward trend. NASDAQ slid 0.18% to $11,313.36, following the last session’s downward trend on what was a somewhat negative trend exchanging session today.

Earnings Per Share

As for profitability, Citius Pharmaceuticals has a trailing twelve months EPS of $-0.202.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -28.48%.

Earnings Before Interest, Taxes, Depreciation, and Amortization

Citius Pharmaceuticals’s EBITDA is -17.59.

Classification of Stock Prices

The stochastic oscillator is a helpful indicator for overbought or oversold situations.

Citius Pharmaceuticals is overbought (>=80).

Yearly Top and Bottom Value

Citius Pharmaceuticals’s stock is valued at $1.19 at 16:33 EST, way under its 52-week high of $2.01 and way above its 52-week low of $0.77.

More news about Citius Pharmaceuticals.

4. DIRTT Environmental Solutions Ltd. (DRTT) – -10.4%

DIRTT Environmental Solutions Ltd. manufactures and installs prefabricated interiors for commercial space use in a variety of industries in the United States and Canada. The company’s ICE interior construction software provides integrated management from design to engineering, production, and installation. Prefabricated interior modules, floors, and ceilings can be customized by the company. It also offers decorative and functional millwork, power infrastructure, network infrastructure, and pre-installed gas piping systems. Through a network independent distributor partners, it offers interior construction solutions. The company serves a variety of industries including healthcare, education and hospitality. It also offers medical gas piping systems to healthcare. DIRTT Environmental Solutions Ltd. is located in Calgary, Canada.

NASDAQ ended the session with DIRTT Environmental Solutions Ltd. sliding 10.4% to $0.78 on Wednesday while NASDAQ dropped 0.18% to $11,313.36.

Earnings Per Share

As for profitability, DIRTT Environmental Solutions Ltd. has a trailing twelve months EPS of $-0.753.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -126.4%.

Earnings Before Interest, Taxes, Depreciation, and Amortization

DIRTT Environmental Solutions Ltd.’s EBITDA is -98.37.

More news about DIRTT Environmental Solutions Ltd..

5. Frequency Therapeutics (FREQ) – -9.04%

Frequency Therapeutics Inc. is a biotech company in clinical stage. It focuses on harnessing the body’s natural biology to reverse or repair damage from a variety of degenerative conditions. The company’s Progenitor Cell Activation method uses small molecules to activate the progenitor cells in the body and create functional tissue. FX-322 is the company’s leading product candidate and is currently in phase IIa clinical trials to address the root cause of sensorineural loss. The company is developing medications for patients with a variety of degenerative conditions including multiple sclerosis and diseases of muscle, skin and bone. Frequency Therapeutics Inc. is a licensed and collaborative partner with Astellas Pharma Inc. to develop and commercialize FX-322. There are also collaboration and licensing agreements between Massachusetts Eye and Ear and Mass General Brigham and the Massachusetts Institute of Technology and The Scripps Research Institute. It was founded in Lexington, Massachusetts in 2014.

NASDAQ ended the session with Frequency Therapeutics dropping 9.04% to $4.98 on Wednesday while NASDAQ dropped 0.18% to $11,313.36.

Earnings per Share

Frequency Therapeutics’ trailing 12 month EPS is $-2.54.

For the 12 trailing months, the company’s return-on-equity, which is a measure of the profitability and shareholder equity for a company, was negative at -74.83%.

Volume

Frequency therapeutics’ last reported volume is now 290549, which is 29.72% more than its average volume at 223975.

Annual Top and Bottom Value

At 16:34 EST Frequency Therapeutics’ stock was valued at $4.98. This is way lower than its 52 week high of $5.79, and far higher than its 52-week lowest of $1.00.

More news about Frequency Therapeutics.

6. Erytech Pharma S.A. (ERYP) – -8.79%

ERYTECH Pharma S.A., a clinical-stage biopharmaceutical company, develops red blood cell-based therapeutics for cancer and orphan diseases in France and the United States. Its lead product candidate is eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing erymethionase, a preclinical product candidate that consists of methionine-?-lyase in red blood cells to target methionine-dependent cancers. It has research collaborations with the Fox Chase Cancer Center to advance the preclinical development of erymethionase for the treatment of homocystinuria; and Queen's University of Canada to advance the preclinical development of eryminase for the treatment of arginase-1-deficiency. The company was incorporated in 2004 and is headquartered in Lyon, France.

NASDAQ ended the session with Erytech Pharma S.A. sliding 8.79% to $0.52 on Wednesday, after two sequential sessions in a row of losses. NASDAQ dropped 0.18% to $11,313.36, following the last session’s downward trend on what was a somewhat down trend trading session today.

Earnings Per Share

As for profitability, Erytech Pharma S.A. has a trailing twelve months EPS of $-4.81.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -91.39%.

Revenue growth

The year-on-year revenue growth fell by 50%, and now stands at 2.86M in the 12 trailing months.

More news about Erytech Pharma S.A..

7. NextEra Energy (NEE) – -8.66%

NextEra Energy, Inc., via its subsidiaries, produces, transmits, distributes, sells, and markets electric power to wholesale and retail customers across North America. It generates electricity using natural gas, wind, solar and nuclear power plants. The company also constructs, operates, and develops long-term contracts that include clean energy solutions such as solar, wind, nuclear, coal, and battery storage. It sells energy commodities and develops electric generators in the wholesale energy market. The company’s net generation capacity was approximately 28.564 megawatts, with approximately 77,000 miles of transmission- and distribution lines. It also had 696 substations. The company serves around 11 million customers through approximately 5.7million customer accounts on the east and west coasts. The original name of the company was FPL Group, Inc., but it changed its name in 2010 to NextEra Energy, Inc. It was established in 1925. The headquarters are located in Juno Beach in Florida.

NYSE ended the session with NextEra Energy sliding 8.66% to $76.63 on Wednesday while NYSE dropped 0.03% to $15,863.19.

Earnings per Share

NextEra Energy’s trailing 12 months EPS is $2.11.

PE Ratio

NextEra Energy’s trailing 12-month price-earnings ratio is 36.32. The purchaser of the shares is therefore investing $36.32 per dollar in annual earnings.

For the 12 trailing months, the company’s return-on-equity, which is an indicator of the business’ profitability relative to shareholders’ equity, was 3.74%.

Annual Top and Bottom Value

NextEra Energy stock was valued at $76.63 as of 16:34 EST. This is way below its 52 week high of $91.35 but well above its low 52-week of $67.22.

Volatility

NextEra Energy last week’s and last month’s intraday variations averages were negative 0.46% and negative 0.10% respectively.

NextEra Energy had the highest average volatility amplitudes of 1.15%, 0.92% and 1.15% in last week.

Dividend Yield

Morningstar, Inc. estimates that the next dividend payment will be made on November 22, 2022. The forward annual dividend rate for 2020 is estimated at 1.7, while the forward annual dividend yield of 2.25% is estimated to be 2.25%.

Sales Growth

NextEra Energy’s sales growth is 6.4% for the present quarter and 35.3% for the next.

More news about NextEra Energy.

8. Fathom Holdings (FTHM) – -7.78%

Fathom Holdings Inc. offers cloud-based brokerage services for real estate in the South Atlantic, Southwest and Western United States. Through its website, www.FathomRealty.com, the company provides access to various properties available for lease or sale to tenants, buyers, landlords and sellers. IntelliAgent is a platform for real estate technology that provides a range of tools and services to agents and brokerages. It includes technology, business processes and business intelligence, reporting and training. Fathom Holdings Inc. is located in Cary in North Carolina.

NASDAQ ended the session with Fathom Holdings dropping 7.78% to $5.69 on Wednesday while NASDAQ dropped 0.18% to $11,313.36.

Earnings Per Share

As for profitability, Fathom Holdings has a trailing twelve months EPS of $-1.02.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -36.04%.

Growth Estimates Quarters

For the current quarter, the company expects a decline of 50% in growth and a rise of 18.9% the following.

More news about Fathom Holdings.

9. DZS (DZSI) – -7.44%

DZS Inc. offers network access solutions for enterprise and service provider networks throughout the Americas, Europe and the Middle East. The company offers mobile transport products that include standard Ethernet/IP and multiprotocol label switch interfaces. This allows mobile operators to upgrade their backhaul and fronthaul systems to support 5G. It also sells broadband access products. These products consist of routing and switching products for service providers and carriers to connect customers residentially and commercially. Connected premises products are made up of indoor/outdoor optic network terminal gateways. Software and services are also offered by the company. These include software-defined networking orchestration solutions and virtualization of network functions, as well as professional and technical support. The company has also formed a partnership with Quanta Cloud Technology and Plume Design, Inc. The business was formerly called DASAN Zhone Solutions, Inc., but it changed its name in August 2020 to DZS Inc. It was established in Plano Texas in 1996.

NASDAQ ended the session with DZS falling 7.44% to $11.94 on Wednesday while NASDAQ fell 0.18% to $11,313.36.

Earnings per Share

DZS’s trailing 12 months profit per share is $-0.53.

For the 12 trailing months, the company’s return-on-equity, which is a measure of the profitability and shareholder equity for a business, was negative at -21.14%.

Revenue growth

The year-over-year revenue growth was 21.5%. We now have 373.58M in the 12 trailing months.

More news about DZS.

10. Cyclerion Therapeutics (CYCN) – -7.36%

Cyclerion Therapeutics, Inc. is a biopharmaceutical company at clinical stage. It focuses on the discovery, development, commercialization, and marketing of medications for severe central nervous system diseases. Its products include CY6463 (a CNS-penetrant soluble guanylate cyclase [sGC] stimulator) that is currently in Phase II trials to treat mitochondrial encephalomyopathy and lactic acidosis (MELAS), and Alzheimer’s Disease with vascular pathology. Olinciguat (orally administered vascular soluble guanylate cyclase stimulation stimulator) that is being studied in Phase II for treatment of sickle cells disease (SGC stimulator) that can be taken orally. It was founded in 2018, and its headquarters are in Cambridge, Massachusetts.

NASDAQ ended the session with Cyclerion Therapeutics falling 7.36% to $0.63 on Wednesday, after two sequential sessions in a row of losses. NASDAQ fell 0.18% to $11,313.36, following the last session’s downward trend on what was a somewhat bearish trend exchanging session today.

Earnings Per Share

As for profitability, Cyclerion Therapeutics has a trailing twelve months EPS of $-2.217.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -106.93%.

More news about Cyclerion Therapeutics.

Stay up to date with our winners and losers daily report